CAR-T cells in refarctory SLE- long term data presented #EULAR2023 Pts did well except some mild cytopenias. Pts remained in remission. Maybe a good option in the near future for refractory pts! @RheumNow https://t.co/NWoFBipOiQ

#EULAR2023 Clinical Highlights. CTD: OP0240 Open label study (N=26) showed stabilisation/improvement in FVC in patients with #ILD treated either Tacrolimus vs MMF. No efficacy difference between both therapies @RheumNow https://t.co/d3rCzNgYHK

Microvascular visualization in Behcet's disease by ultrasound. Maybe really useful in cases which are difficult to diagnose and may not need biopsies in some pts. #EULAR2023 @RheumNow https://t.co/PbC3tCe7v6

Denosumab in hand OA prevented erosions! #eular2023 @RheumNow https://t.co/Ij2CVjh1ET

New treatment target for #gout #EULAR2023 SEL-212 - 2 drugs one after the other! - tolerogenic nanoparticles containing rapamycin followed by pegadricase -only 50% reponded, but there were pts who didn't respond at all. @RheumNow https://t.co/RXK58piU85

Treat early it is also cheaper! 5 yr cost of RA ttmt €11250 ACPA+ > €3526 ACPA- bDMARDS users €44788 ACPA+ > €40896 ACPA- ACPA- "late" ttmt 46% more expensive ACPA+ early vs. late = similar costs @Rheumnow #EULAR23 POS0369 https://t.co/dg9T9fqJDl

#EULAR2023 Clinical Highlights. Vasculitis: OP0061 - new US imaging showing vessel inflammation differentiating patients with Behcet’s vs No-BD. OP0304: cohort study showed Benralizumab (IL5 RA) given for eosinophilic asthma also improved BVAS. RCT for EGPA is ongoing @RheumNow https://t.co/7uohfjGk49

With the single cell RNA sequencing analysis being my more affordable (relatively) and widely used! Science is moving forward. Highlights in basic science and translational data #EULAR2023 @RheumNow https://t.co/sS7xLeNyLW

#EULAR2023 Clinical Highlights. SpA: OP0059 H2H RCT of SEC vs ADA Biosimilar in bDMARDs naive showed no difference in imaging progression at 2yrs. OP0061 Pooled analyses of UPA RCTs showed low rates of Extra-articular Manifestation. Numerically lower vs PBO for Uveitis @RheumNow https://t.co/GoUPfpwTLq

Biosimilars cost less, but do they incur in indirect costs due to less dis control or more AE? DANBIO study (>1,300 pts w/ IA) Costs similar or decreased 9 mo after mandatory switching to ADA biosimilar (GP2017 or SB5) Decrease 15% GP2017 switchers #EULAR23 POS0376 @RheumNow https://t.co/bAeqYhNgf0

#EULAR2023 Clinical Highlights. Osteoarthritis. OP0071 Single centre Phase 2 RCT showed Denosumab halted erosion in Erosive OA at 24 weeks treatment, and the treatment effect enhances after 48 weeks vs PBO @RheumNow https://t.co/YWFUg3cp7P

Nocicpetor ablation in mice model with #OA - pain was reduced. If its done before OA progression, it helps, but after it doesnt! @AM_Malf work highligted at #EULAR2023 @RheumNow https://t.co/zvxHmlCIrD